On September 29, SKB BIO rose 4.17% in regular trading, trading at 472.2 HKD/share, with turnover of approximately 90.72 million HKD.
On the news front, the company recently announced that multiple Phase III clinical studies of its independently developed TROP2 ADC sacituzumab have been selected as Late-Breaking Abstracts at the upcoming European Society for Medical Oncology (ESMO) annual meeting in October, and will be presented as oral presentations. Additionally, the broader biotech sector rallied strongly, with AKESO surging 11.96% and other peers posting notable gains, creating sector-wide momentum.
From a fundamental perspective, SKB BIO reported first-half revenue of RMB 978 million, with drug sales reaching RMB 657 million, up 112% year-over-year. The company achieved its first-ever profit since listing, posting adjusted net profit of RMB 479 million. Gross margin improved to 75.3% from 69.4% a year earlier. Multiple investment banks recently raised target prices, with UBS setting 678 HKD, Bank of America at 644.4 HKD, and CLSA at 626.4 HKD, all maintaining buy ratings, citing accelerating commercialization and the global development prospects of sac-TMT as a cornerstone ADC asset.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments